Sentences with phrase «laboratory medicine cancer»

Not exact matches

Baldrick's Foundation Pediatric Cancer Dream Team and Associate Director, Stanford Cancer Institute; Co-medical Director, Standford Laboratory for Cell and Gene Medicine Dr. Gabriel Otte, Co-founder and CEO, Freenome Inc..

Åbo Akadmi University, Finland Amity University, India Carnegie Mellon University with Steiner Studios Cornell University Columbia University and the City University of New York The Cooper Union École Polytechnique Fédérale de Lausanne, Switzerland Indian Institute of Technology Bombay, India Korea Advanced Institute of Science and Technology, Korea New York University, Carnegie Mellon, the City University of New York, the University of Toronto, and IBM The New York Genome Center, with Albert Einstein College of Medicine, Columbia University Medical Center, Memorial Sloan Kettering Cancer Center, Mount Sinai School of Medicine, New York University, Rockefeller University, and the Jackson Laboratory Purdue University Rensselaer Polytechnic Institute Stanford University The Stevens Institute of Technology Technion - Israel Institute of Technology, Israel The University of Chicago The University of Warwick, United Kingdom

Remarkably, researchers from the Department of Laboratory Medicine and Pathobiology (LMP) have defined potential treatment targets for this relatively common cancer — providing hope for future patients.

The research team, including Soumen Paul, Ph.D., associate professor, Arindam Paul, Ph.D., assistant professor, and Ossama Tawfik, professor, M.D., Ph. D., all in the Department of Pathology and Laboratory Medicine, and their colleagues, studied atypical protein kinase c lambda / iota signaling during the invasive progression of triple - negative breast cancer.

Fully implemented targeted sequencing - based assays in routine diagnostic pathology laboratories are currently lacking in lymphoid cancer care,» explained Christian Steidl, MD, Senior Scientist at the BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Ccancer care,» explained Christian Steidl, MD, Senior Scientist at the BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, CCancer and Associate Professor in the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

«These findings suggest that BLBC cells have an innate ability to establish a local microenvironment that is supportive of cancer stem cells,» explained Thiagalingam, associate professor in Genetics & Genomics, Medicine, and Pathology & Laboratory Medicine, at BUSM.

«A lot of the genes that cause the original cancer are also potentially responsible for the metastatic process, and the cancer may not need to acquire new traits to be able to spread to distant sites,» said UNC Lineberger's Charles M. Perou, PhD, the May Goldman Shaw Distinguished Professor of Molecular Oncology, and a professor of Genetics and Pathology & Laboratory Medicine.

«By combining my laboratory's expertise in ovarian cancer biology and Dr. Xu's expertise in bioinformatics, we were able to uncover a potentially novel drug approach to treat ovarian cancer,» said co-senior author Analisa DiFeo, PhD, the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of Medcancer biology and Dr. Xu's expertise in bioinformatics, we were able to uncover a potentially novel drug approach to treat ovarian cancer,» said co-senior author Analisa DiFeo, PhD, the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of Medcancer,» said co-senior author Analisa DiFeo, PhD, the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of MedCancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of MedCancer Center at Case Western Reserve University School of Medicine.

New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumor reappears.

The results of the study were published this week in the journal Nature Medicine from researchers at Penn's Abramson Cancer Center, including senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the ACC, the University of Maryland School of Medicine, and Adaptimmune Therapeutics plc (Adaptimmune).

Arizona State University Army Research Lab, Weapons and Materials Research Directorate Baylor School of Medicine Carnegie Mellon University Case Western Reserve University CIIT Centers for Health Research Columbia University Cornell University Emory University School of Medicine Fred Hutchinson Cancer Research Center J. David Gladstone Institute Harvard University Medical School Indiana University, Bloomington Johns Hopkins School of Medicine Los Alamos National Laboratory Lawrence Livermore National Laboratory Louisiana State University Health Sciences Center Massachusetts General Hospital Massachusetts Institute of Technology McGill University MCP Hahnemann Medical School Medical College of Georgia Medical College of Wisconsin Microsoft NCI NIEHS NIH NOAA New York University School of Medicine Penn State University College of Medicine Pfizer Rockefeller University Rowland Institute for Science Seattle Biomedical Research Institute St. Jude Children's Research Hospital Stanford University USEPA / National Risk Management Research Lab University of Alabama, Birmingham University of California, Berkeley University of California, Los Angeles University of California, San Diego University of California, San Francisco University of Chicago University of Cincinnati College of Medicine University of Colorado at Boulder University of Georgia University of Illinois, Chicago University of Illinois, Urbana - Champagne University of Maryland University of Medicine and Dentistry of New Jersey University of Michigan University of Minnesota University of New Mexico University of North Carolina, Chapel Hill University of Pennsylvania University of Rochester School of Medicine and Dentistry University of Texas, Austin University of Texas Medical Branch University of Toronto University of Wisconsin, Madison Vanderbilt University Virginia Tech Yale University

Soon other researchers began to find more connections between microRNA and cancer, and microRNA research began to spread through medicine and biology — in David Baltimore's words, like «an infection in the laboratory.»

«Having these personalized laboratory models, which we can make in a matter of weeks, will let us test multiple different drugs on the tumor and help us bring precision medicine to individuals with bladder cancer.»

The current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.

The lab of senior author David Roth, MD, PhD, chair of the Department of Pathology and Laboratory Medicine, has been working out the cancer - related intricacies of V (D) J recombinase for the last two decades.

Subsequent laboratory testing of the platform will include rats, she said, followed by testing on dogs that are already scheduled for cancer surgeries at the College of Veterinary Medicine.

The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

Dr. Bauman collaborated with Daniel E. Johnson, Ph.D., professor of medicine at Pitt and a senior scientist in the UPCI Head and Neck Cancer Program, to test sulforaphane in the laboratory.

Dr. David Gilley's laboratory at the Indiana University School of Medicine in Indianapolis and Dr. Connie Eaves» laboratory at the BC Cancer Agency's Terry Fox Laboratory in Vancouver, Canada, collaborated to determine how telomeres are regulated in different types of normal brelaboratory at the Indiana University School of Medicine in Indianapolis and Dr. Connie Eaves» laboratory at the BC Cancer Agency's Terry Fox Laboratory in Vancouver, Canada, collaborated to determine how telomeres are regulated in different types of normal brelaboratory at the BC Cancer Agency's Terry Fox Laboratory in Vancouver, Canada, collaborated to determine how telomeres are regulated in different types of normal breLaboratory in Vancouver, Canada, collaborated to determine how telomeres are regulated in different types of normal breast cells.

«An important translational implication of this research is that we hope that by combining Notch inhibitors with drugs that target B - cell signaling we can better treat these B - cell cancers,» said senior author Warren Pear, MD, PhD, a professor of Pathology and Laboratory Medicine at Penn Medicine.

Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork - Presbyterian Hospital, The New York Stem Cell Foundation, New York University, Northwell Health, Princeton University, The Rockefeller University, Roswell Park Cancer Institute, Stony Brook University, Weill Cornell Medicine and IBM.

Additional funding from the Alvin J. Siteman Cancer Center / Barnes Jewish Hospital Foundation Cancer Frontier Fund, the Barnard Trust, the Philip and Sima Needleman Student Fellowship in Regenerative Medicine, the DeNardo Education and Research Foundation, Alafi Neuroimaging Laboratory, and the Hope Center for Neurological Disorders.

In a meeting sponsored by the National Cancer Policy Forum of the National Academies» Institute of Medicine in Washington, D.C., Fan and 15 other experts in the field described the benefits of using pet dogs with naturally occurring (rather than laboratory - induced) tumors in early cancer drug tCancer Policy Forum of the National Academies» Institute of Medicine in Washington, D.C., Fan and 15 other experts in the field described the benefits of using pet dogs with naturally occurring (rather than laboratory - induced) tumors in early cancer drug tcancer drug trials.

He is also responsible for laboratory testing in Emergency Medicine and Cardiology, and is involved in development of new prostate cancer biomarkers.

In my laboratory at NYU Langone, I focus on precision medicine, rare tumors, and early detection and prevention of gynecologic cancers.

Participating institutions: Helmholtz Association • CNRS • Institute of Molecular Biotechnology • Research Center for Molecular Medicine of the Austrian Academy of Sciences • VIB - KU Leuven • Friedrich Miescher Institute for Biomedical Research • University of Basel • University of Zurich • Central European Institute of Technology • Max Planck Institute of Immunobiology and Epigenetics • Max Planck Institute for Molecular Genetics • German Cancer Research Center • Max Delbrück Center for Molecular Medicine • German Center for Neurodegenerative Diseases • Helmholtz Zentrum München • Max Planck Institute for Evolutionary Anthropology • Helmholtz Institute of RNA - based Infection Research • Saarland University • Technical University Munich • University of Würzburg • Biotech Research & Innovation Centre • Interdisciplinary Nanoscience Center • University of Copenhagen • Centre for Genomic Regulation • Institut Curie • Université de Montpellier • Inserm • Université Toulouse III — Paul Sabatier • École nationale supérieure des mines de Paris • Institute for Molecular Medicine Finland • The Biomedical Research Foundation, Academy of Athens • Weizmann Institute of Science • Hebrew University • Sapienza — University of Rome • Instituto Nazionale Genetica Molecolare • University of Napoli • University of Padua • University of Milan • European Institute of Oncology • Netherlands Cancer Institute • Radboud University • University Medical Center Utrecht • Hubrecht Institute • Instituto Gulbenkian de Ciência • Institute of Bioorganic Chemistry of the Polish Academy of Sciences • Romanian Center for Systems Immunology • Karolinska Institute • MRC Human Genetics Unit • University of Edinburgh • Wellcome Sanger Institute • The Babraham Institute • European Molecular Biology Laboratory — European Bioinformatics Institute

He joined UCSF in 2015, where he continues his research on developing personalized cancer medicine by translating laboratory studies into improvements in patient care.

The study conducted in the laboratory of Don Cleveland, Ph.D., UCSD Professor of Medicine, Neurosciences and Cellular and Molecular Medicine and member of the Ludwig Institute for Cancer Research, shows that therapeutic molecules known as antisense oligonucleotides can be delivered to the brain and spinal cord through the cerebrospinal fluid (CSF) at doses shown to slow the progression of ALS in rats.

Dr. Carl H. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and the director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania.

Included among the numerous recipients of Mr. Sanford's gifts, that total more than one billion dollars, are: the Edith Sanford Foundation for Breast Cancer that was created in 2012 by a gift of $ 100 million in honor of Mr. Sanford's mother who died of breast cancer when he was four years old; the Sioux Valley Hospitals and Health System, which renamed itself Sanford Health in 2007, in recognition of a $ 400 million gift; a $ 125 million gift in 2014 to establish Sanford Imagenetics, a program that will integrate genomic medicine into primary care for adults; the University of California San Diego which received a $ 100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $ 50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $ 20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $ 70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative MedCancer that was created in 2012 by a gift of $ 100 million in honor of Mr. Sanford's mother who died of breast cancer when he was four years old; the Sioux Valley Hospitals and Health System, which renamed itself Sanford Health in 2007, in recognition of a $ 400 million gift; a $ 125 million gift in 2014 to establish Sanford Imagenetics, a program that will integrate genomic medicine into primary care for adults; the University of California San Diego which received a $ 100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $ 50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $ 20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $ 70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative Medcancer when he was four years old; the Sioux Valley Hospitals and Health System, which renamed itself Sanford Health in 2007, in recognition of a $ 400 million gift; a $ 125 million gift in 2014 to establish Sanford Imagenetics, a program that will integrate genomic medicine into primary care for adults; the University of California San Diego which received a $ 100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $ 50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $ 20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $ 70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative Mmedicine into primary care for adults; the University of California San Diego which received a $ 100 million gift for the creation of the Sanford Stem Cell Clinical Center in 2013 to accelerate the translation of stem cell research discoveries by advancing clinical trials and patient therapies; the Burnham Institute for Medical Research that received a $ 50 million gift in 2010, and recognized its appreciation for both this and a 2008 gift of $ 20 million to the Sanford Center for Childhood Disease research at Burnham by then changing its name to Sanford Burnham Medical Research Institute; a $ 70 million gift to establish a particle physics laboratory named the Sanford Underground Research Facility; and the San Diego Consortium for Regenerative Medicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative MMedicine which received a gift of $ 30 million in 2008 and expressed its gratitude by renaming itself the Sanford Consortium for Regenerative MedicineMedicine.

A surgeon, educator and researcher, Kandel comes to UChicago Medicine from Columbia University College of Physicians and Surgeons in New York where she served as the R. Peter Altman Professor of Surgery and Pediatrics in the Institute for Cancer Genetics and co-director of its Pediatric Tumor Biology Laboratory.

Carl - Henrik Heldin has been or is a member of Scientific Advisory Boards of several institutes and companies, including the European Molecular Biology Laboratory and the German Cancer Center in Heidelberg, the Center for Molecular Medicine in Vienna and the Finnish Institute for Molecular Medicine in Helsinki.

«Basically, this study shows that the genetic makeup of individual human embryonic stem cell lines is unique in the numbers of copies of certain genes that may control traits and things like disease susceptibility,» said Teitell, who also is an associate professor of pathology and laboratory medicine and a researcher at UCLA's Jonsson Comprehensive Cancer Center.

Developed in collaboration with the Laboratory Medicine, Information Technology and Health Science Research departments of Mayo Clinic Geneticist Assistant NGS Interpretative Workbench, is a web - based tool for the control, visualization, interpretation and historical knowledge base of next generation sequencing data targeted at specific genes for the purpose of identifying potentially pathogenic variants associated with specific conditions such as hereditary colon cancer.

Examples are the inaugural Morton K. Schwartz Award for Cancer Research Diagnostics, Albert Nichols Award for strategic innovation in laboratory medicine, Norman Kubasik Award for Outstanding contribution to the education of clinical laboratory scientists, Bernard Gerulat Award for outstanding achievement in clinical chemistry, Carl R. Joliff Award for Outstanding achievement in diagnostic immunology and education, Miriam Reiner Award for outstanding contributions to research in the field of clinical chemistry and Outstanding Contribution to Clinical Chemistry in Research Award (all from the AACC).

This study, published in Nature Medicine, tested a novel CAR that was developed in the Mackall laboratory at the National Cancer Institute (NCI) in a first - in - human, first - in - child study conducted by Drs. Fry, Shah, and colleagues in the NCI Center for Cancer Research's Pediatric Oncology Branch at the NIH Clinical Center.

In addition to serving as Director of the Laboratory of Molecular Medicine, Dr. Beliveau is a researcher in the Neurosurgery Department of Notre - Dame Hospital and the hemato - oncology unit of Sainte - Justine Hospital and holds several prestigious academic positions, including: Chaire de Neurochirurgie Claude - Bertrand, full professor of biochemistry at Université du Québec à Montréal, professor of surgery and physiology on the medicine faculty of Université de Montréal, and Chaire en Prévention et Traitement duMedicine, Dr. Beliveau is a researcher in the Neurosurgery Department of Notre - Dame Hospital and the hemato - oncology unit of Sainte - Justine Hospital and holds several prestigious academic positions, including: Chaire de Neurochirurgie Claude - Bertrand, full professor of biochemistry at Université du Québec à Montréal, professor of surgery and physiology on the medicine faculty of Université de Montréal, and Chaire en Prévention et Traitement dumedicine faculty of Université de Montréal, and Chaire en Prévention et Traitement du Cancer.

The Center for Personalized Diagnostics (CPD) is a joint initiative between Penn Medicine's Department of Pathology and Laboratory Medicine and the Abramson Cancer Center.

She has established the state - of - the - art laboratory of cancer genomics and molecular diagnostics (together supporting genomic medicine).

For example, the translational laboratory is providing support to a precision medicine - based clinical trial for patients with early - stage, triple - negative breast cancer.

Prior to joining CHLA in 2015, Dr. Biegel rose through the academic ranks to Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and was the founding director of the Cancer Cytogenetics Laboratory at The Children's Hospital of Philadelphia.

Glickman Urological and Kidney Institute - Urology Lerner Research Institute - Cancer Biology Taussig Cancer Institute Pathology and Laboratory Medicine Institute - Pathology

Michael Berger, Memorial Sloan Kettering Cancer Center Wendy Chung, Columbia University Paul Flicek, European Bioinformatics Institute Geoffrey Ginsburg, Duke University School of Medicine Eric Green, National Human Genome Research Institute Elaine Mardis, Nationwide Children's Hospital Howard McLeod, Moffitt Cancer Center Len Pennacchio, DOE Joint Genome Institute, Lawrence Berkeley National Laboratory Heidi Rehm, Harvard, Broad Institute Mike Talkowski, Harvard, Broad Institute

Pathology and Laboratory Medicine Institute - Laboratory Medicine Taussig Cancer Institute - Hematology and Oncology; Translational Hematology and Oncology Research

Dr. Smith, a professor in the Department of Laboratory Medicine and Pathology, wears many hats at the Mayo Clinic, including running a lab where he works on the characterization of the common fragile sites in the genome and on the role that human papillomaviruses play in the development of a variety of different cancers.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

Scientist, Integrative Oncology, BC Cancer Agency Assistant Professor, Pathology and Laboratory Medicine, University of British Columbia

BSc (Microbiology and Immunology), University of British Columbia, 2004 PhD (Pathology and Laboratory Medicine), University of British Columbia, 2009 Post-Doctoral Fellow (Cancer Biology and Genetics), with Harold Varmus, Memorial Sloan - Kettering Cancer Center, 2009 - 2010 Post-Doctoral Fellow (Cancer Genetics), with Harold Varmus, National Human Genome Research Institute, 2010 - 2014

Director, The University of Chicago Comprehensive Cancer Center Director, Cancer Cytogenetics Laboratory Professor of Medicine, Section of Hematology / Oncology

Leaders from The Tisch Cancer Institute at the Icahn School of Medicine and the Lillian and Henry M. Stratton - Hans Popper Department of Pathology and Laboratory Medicine at the Mount Sinai Health System served as associate directors of the symposium.